

**Freedom of Information Act 2000 - Request Reference FoI/23/430**

**Treatment for inflammatory diseases**

**Information Requested:**

**Q1 – How many patients were treated with the following drugs for the following diseases in the 3 months between the start of May 2023 and the end of July 2023?**

*Please use the latest available 3 months if May to July is not available and specify which 3 months has been used. Please ignore any cells which have been blanked out.*

| Drug Name                | Plaque psoriasis | Crohn's Disease | Ulcerative colitis | Psoriatic arthritis | Ankylosing spondylitis (inc. axial spondylitis) | Rheumatoid arthritis |
|--------------------------|------------------|-----------------|--------------------|---------------------|---|----------------------|
| Adalimumab (Humira)      |                  |                 |                    |                     |   |                      |
| Adalimumab (Biosimilars) |                  |                 |                    |                     |   |                      |
| Apremilast               |                  |                 |                    |                     |   |                      |
| Bimekizumab              |                  |                 |                    |                     |   |                      |
| Brodalumab               |                  |                 |                    |                     |   |                      |
| Certolizumab Pegol       |                  |                 |                    |                     |   |                      |
| Deucravacitinib          |                  |                 |                    |                     |   |                      |
| Etanercept (Enbrel)      |                  |                 |                    |                     |   |                      |
| Etanercept (Biosimilars) |                  |                 |                    |                     |   |                      |
| Guselkumab               |                  |                 |                    |                     |   |                      |
| Infliximab (Remicade)    |                  |                 |                    |                     |   |                      |
| Infliximab (Biosimilars) |                  |                 |                    |                     |   |                      |
| Ixekizumab               |                  |                 |                    |                     |   |                      |
| Risankizumab             |                  |                 |                    |                     |   |                      |
| Secukinumab              |                  |                 |                    |                     |   |                      |
| Tildrakizumab            |                  |                 |                    |                     |   |                      |
| Ustekinumab              |                  |                 |                    |                     |   |                      |
| Upadacitinib             |                  |                 |                    |                     |   |                      |
| Vedolizumab              |                  |                 |                    |                     |   |                      |
| Filgotinib               |                  |                 |                    |                     |   |                      |
| Golimumab                |                  |                 |                    |                     |   |                      |
| Mirikizumab              |                  |                 |                    |                     |   |                      |
| Ozanimod                 |                  |                 |                    |                     |   |                      |
| Tofacitinib              |                  |                 |                    |                     |   |                      |

|             |  |  |  |  |  |
|-------------|--|--|--|--|--|
| Abatacept   |  |  |  |  |  |
| Baricitinib |  |  |  |  |  |
| Rituximab   |  |  |  |  |  |
| Sarilumab   |  |  |  |  |  |
| Tocilizumab |  |  |  |  |  |

In completing a search for the information requested, Cardiff and Vale University Health Board (the UHB) has confirmed that this information is not centrally recorded or collated. To retrieve the information requested would require a manual search through individual patient records and the UHB considers that this would exceed the limit set within regulations for responding to a request. The UHB has therefore relied upon the Section 12 exemption ('Exemption where cost of compliance exceeds appropriate limit') of the Freedom of Information Act 2000 and is refusing your request.

The UHB has estimated that to complete the work needed to respond to this request would exceed the time limit as set within regulations to respond to a Freedom of Information Act request. Under the Act there is an allowance of two and a half days, or 18 hours, to comply with a request and the cost limit set within the fees' regulations for this amount of work (18 hours) is £450 for the UHB. The fees regulations specify that the cost of complying with a request must be calculated at the rate of £25 per hour.

**Q2 – How many patients were treated with the following drugs from the following departments (for any disease) in the 3 months between the start of May 2023 and the end of July 2023?**

*Please use the latest available 3 months if May to July is not available and specify which 3 months has been used.*

| Drug Name                | Dermatology | Gastroenterology | Rheumatology |
|--------------------------|-------------|------------------|--------------|
| Adalimumab (Humira)      | 11          | 4                | 33           |
| Adalimumab (Biosimilars) | 144         | 271              | 236          |
| Apremilast               | 2           | 0                | 0            |
| Bimekizumab              | 8           | 0                | 0            |
| Brodalumab               | 5           | 0                | 0            |
| Certolizumab Pegol       | 5           | 0                | 100          |
| Deucravacitinib          | 0           | 0                | 0            |
| Etanercept (Enbrel)      | 0           | 0                | 23           |
| Etanercept (Biosimilars) | 5           | 0                | 183          |
| Guselkumab               | 17          | 0                | 3            |
| Infliximab (Remicade)    | 0           | 0                | 2            |
| Infliximab (Biosimilars) | 18          | 8                | 18           |
| Ixekizumab               | 12          | 0                | 6            |
| Risankizumab             | 42          | 0                | 0            |
| Secukinumab              | 31          | 0                | 32           |
| Tildrakizumab            | 1           | 0                | 0            |

|              |    |     |     |
|--------------|----|-----|-----|
| Ustekinumab  | 40 | 124 | 16  |
| Upadacitinib | 5  | 3   | 10  |
| Vedolizumab  | 0  | 157 | 0   |
| Filgotinib   | 0  | 21  | 1   |
| Golimumab    | 0  | 2   | 40  |
| Mirikizumab  | 0  | 0   | 0   |
| Ozanimod     | 0  | 0   | 0   |
| Tofacitinib  | 1  | 4   | 9   |
| Abatacept    | 0  | 0   | 52  |
| Baricitinib  | 6  | 0   | 46  |
| Rituximab    | 0  | 0   | 42  |
| Sarilumab    | 0  | 0   | 14  |
| Tocilizumab  | 0  | 0   | 101 |